Goettingen | Leipzig, Germany, May 3, 2012 - Sartorius
Stedim Biotech, a leading international pharma and biotech
supplier, and the biotechnology specialist c LEcta,
announce the signing of a worldwide sales and distribution
agreement for c LEcta's proprietary Serratia marcescens
nuclease for biopharmaceutical applications. The German
company specializes in the development of customized
enzymes and production strains for industrial applications.
Based on this agreement, customized endonuclease will now
be available under the product name "Denarase" through all
regular Sartorius Stedim Biotech sales channels.
Endonucleases are used in various biopharmaceutical
production processes, such as in recombinant protein
production, to remove nucleic acids, reduce viscosity
levels and thus optimize process efficiencies. The company
c-LEcta has optimized the production process for Serratia
marcescens nuclease using a genetically engineered Bacillus
strain to increase enzyme activity yields and remove
endotoxins. As a result, this new technology enables the
highest purity and quality nuclease to be produced.
"This endonuclease provides outstanding advantages from
which our customers will benefit directly, such as cost
efficiency and high performance," says Dr. Uwe Gottschalk,
Vice President of Purification Technologies at Sartorius
Stedim Biotech. "The nuclease is a perfect addition to our
current purification product portfolio and supports our
strategy as a total solution provider for the
biopharmaceutical industry."
Dr. Marc Struhalla, Managing Director of c-LEcta comments,
"The technology developed by c-LEcta allows us to provide
nuclease to our customers in the highest quality. We are
convinced that with Sartorius Stedim Biotech, we have found
the right sales and distribution partner for the successful
worldwide commercialization of our product."
c-LEcta is a German biotechnology company specializing in the development of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering allows efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes from biodiversity and for effective enzyme engineering.
distributed by |